|
Contact
|
Newsletter
|
Deutsch
Home
Subgroups
Bayer AG (Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Topics
Business & Finance
Research & Innovation
Products
Responsible Care
Social Responsibility
Bayer People
Europe
North America
Asia & Pacific
Central-/Latin America
Africa & Middle East
Press Contact
Bayer AG
(Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Photo-Service
Biographies
Board of Management
Subgroups
Speeches
Photos
Bayer AG (Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Education and Training
Research
Locations
Environmental Protection
BayKomm
TV Service
Business & Finance
Research & Innovation
Products
Responsible Care
Social Responsibility
Bayer People
Europe
North America
Asia & Pacific
Central-/Latin America
Africa & Middle East
Bayer Links
Bayer Global
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Special Interest
Investor Relations
Jobs and Career
Foundations
Sports
Culture
General Conditions of Use
Privacy Statement
Imprint
Topics
Products
|
1 - 20
|
21 - 40
|
41 - 60
|
|
Thursday - November 19, 2009
Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE
Friday - October 23, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
Thursday - October 8, 2009
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany
Wednesday - August 19, 2009
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction
Wednesday - July 22, 2009
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies
Wednesday - July 22, 2009
Pharmaceutical quality acetonitrile
Bayer Technology Services has developed a purification process for acetonitrile
Conventional product can be purified for 10 to 17 euros per liter ACN.
Tuesday - June 30, 2009
Bayer MaterialScience invests in innovative technology for the future
Unique expertise in automotive polycarbonate glazing
New two-component injection molding machine paves the way for further technology enhancements and even better customer service / Rear windows a further focus of development / High-performance coating pilot plant integrated in the BayVision® concept
Tuesday - June 30, 2009
New injection molding system as an innovation platform for technology, application and material development
Film insert molding for large glazing applications with polycarbonate
Excellent molded part quality thanks to adapted process and mold technology
Monday - June 15, 2009
New film enables production of unmistakable, unique IDs
Cards stacked against counterfeiters
Excellent potential also for logistics, brand protection and labeling
Monday - June 1, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
Thursday - May 28, 2009
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
U.S. FDA Issues Complete Response Letter for Rivaroxaban
No new clinical or non-clinical studies to be conducted as a pre-requisite for approval
Friday - May 22, 2009
45th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506
Wednesday - May 20, 2009
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
Friday - May 15, 2009
Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
Thursday - May 14, 2009
Qlaira® – innovative estradiol-based oral contraceptive available in Europe from May onwards
A new oral contraceptive delivering the same estrogen as produced by the female body
Tuesday - May 5, 2009
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
Monday - April 27, 2009
Phase III Trial of Nexavar® in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Study stopped based on interim analysis
Wednesday - April 1, 2009
Bayer MaterialScience at the European Coatings Show 2009
Bayhydrol® – “green” coating raw materials
New nomenclature for waterborne polymer dispersions
Wednesday - April 1, 2009
Bayer MaterialScience at the European Coatings Show 2009
Bayhydur® – crosslinking experience and progress
New hydrophilic polyisocyanates round out the system toolbox for waterborne polyurethane coating systems
|
1 - 20
|
21 - 40
|
41 - 60
|
|
Print page
Search
Advanced Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
We will keep you informed about the latest news.
Events
Friday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact:
Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection
Your selection:
0
Download(s)